About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker KPTI · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 4, 2026Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389 · Myelofibrosis
Selinexor, Selinexor
KPTI
Karyopharm Therapeutics Inc
Phase 3Active, not recruiting353Feb 20, 2026Registry ↗
Oct 29, 2026Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanc…
NCT05611931 · Endometrial Cancer
Selinexor, Matching Placebo for selinexor
KPTI
Karyopharm Therapeutics Inc
Phase 3Active, not recruiting257May 22, 2026Registry ↗
Oct 29, 2026A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM…
NCT04414475 · Multiple Myeloma, Refractory
Selinexor, Dexamethasone
KPTI
Karyopharm Therapeutics Inc
Phase 2Recruiting127Jan 2028Registry ↗
Oct 9, 2026Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepat…
NCT04256707 · Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (C…
Selinexor 100 mg, Docetaxel
KPTI
Karyopharm Therapeutics Inc
Phase 1/2Completed80Jul 31, 2024Registry ↗
Oct 2, 2026A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patien…
NCT04442022 · Relapsed/Refractory Diffuse Large B-cell Lymphoma
Selinexor (combination therapy), Selinexor (combination the…
KPTI
Karyopharm Therapeutics Inc
Phase 2/3Active, not recruiting501Dec 2026Registry ↗
Oct 1, 2026Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251 · Diffuse Large B-cell Lymphoma
Selinexor, Selinexor
KPTI
Karyopharm Therapeutics Inc
Phase 2Active, not recruiting244Dec 2026Registry ↗
Jul 15, 2026Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02343042 · Multiple Myeloma
Selinexor, Dexamethasone
KPTI
Karyopharm Therapeutics Inc
Phase 1/2Recruiting300Apr 2027Registry ↗
Jul 2, 2026A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previousl…
NCT04562870 · Myelofibrosis
Selinexor, Physician's Choice Treatment
KPTI
Karyopharm Therapeutics Inc
Phase 2Active, not recruiting112Sep 2026Registry ↗
Apr 13, 2026Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial…
NCT03555422 · Endometrial Cancer
Selinexor, Matching placebo for selinexor
KPTI
Karyopharm Therapeutics Inc
Phase 3Completed263Jan 22, 2022Registry ↗
Mar 2, 2026Karyopharm Expanded Access Program for Selinexor
NCT07215832 · Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL)
selinexor
KPTI
Karyopharm Therapeutics Inc
—Available——Registry ↗
Feb 12, 2026A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Th…
NCT05980806 · Myelofibrosis, Moderate Thrombocytopenia
Selinexor 60 mg, Selinexor 40 mg
KPTI
Karyopharm Therapeutics Inc
Phase 2Recruiting58Jun 2027Registry ↗
Oct 3, 2025Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With…
NCT04607772 · Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Selinexor, Rituximab
KPTI
Karyopharm Therapeutics Inc
Phase 1/2Withdrawn0Dec 2025Registry ↗
Mar 19, 2025Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory…
NCT02649790 · Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Col…
KPT-8602, ASTX727
KPTI
Karyopharm Therapeutics Inc
Phase 1/2Completed277Aug 31, 2024Registry ↗
Dec 16, 2024A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent…
NCT04421378 · Glioblastoma Multiforme
Selinexor, Temozolomide (TMZ)
KPTI
Karyopharm Therapeutics Inc
Phase 1/2Terminated74Jul 3, 2023Registry ↗
Nov 25, 2024PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
NCT02702492 · Solid Tumors, NHL
KPT-9274, Niacin ER
KPTI
Karyopharm Therapeutics Inc
Phase 1Terminated60Jan 26, 2021Registry ↗
Aug 23, 2024Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
NCT04768881 · Locally Advanced Unresectable or Metastatic Melanoma
Selinexor, Pembrolizumab
KPTI
Karyopharm Therapeutics Inc
Phase 2Terminated15Sep 22, 2023Registry ↗
Aug 21, 2024Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
NCT03110562 · Multiple Myeloma
Selinexor, Bortezomib
KPTI
Karyopharm Therapeutics Inc
Phase 3Completed402Feb 18, 2020Registry ↗
Jan 8, 2024A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sar…
NCT01896505 · Sarcoma
KCP-330
KPTI
Karyopharm Therapeutics Inc
Phase 1Completed54Oct 21, 2016Registry ↗
Nov 3, 2023A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Stand…
NCT04854434 · Metastatic Colorectal Cancer
Selinexor, Pembrolizumab
KPTI
Karyopharm Therapeutics Inc
Phase 2Terminated13Jun 24, 2022Registry ↗
Jan 26, 2023Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multipl…
NCT02628704 · Multiple Myeloma
Selinexor, Placebo (for selinexor)
KPTI
Karyopharm Therapeutics Inc
Phase 2Withdrawn0Jun 2017Registry ↗
Jan 26, 2023Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome…
NCT02431351 · Myelodysplastic Syndrome
Selinexor
KPTI
Karyopharm Therapeutics Inc
Phase 2Withdrawn0Dec 2017Registry ↗
Jan 26, 2023Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myelom…
NCT02389543 · Multiple Myeloma
Selinexor, Lenalidomide
KPTI
Karyopharm Therapeutics Inc
Phase 1/2Withdrawn0Jan 2018Registry ↗
Jan 26, 2023Selinexor Treatment of Refractory Myeloma
NCT02336815 · Multiple Myeloma
Selinexor, Dexamethasone
KPTI
Karyopharm Therapeutics Inc
Phase 2Completed202Jul 26, 2019Registry ↗
Jan 26, 2023Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cuta…
NCT02314247 · Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphom…
Selinexor
KPTI
Karyopharm Therapeutics Inc
Phase 2Terminated16Jan 2016Registry ↗
Jan 26, 2023Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
NCT02213133 · Squamous Cell Carcinoma
Selinexor (KPT-330)
KPTI
Karyopharm Therapeutics Inc
Phase 2Terminated45Dec 10, 2015Registry ↗
Jan 26, 2023SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
NCT02146833 · Prostate Cancer
Selinexor
KPTI
Karyopharm Therapeutics Inc
Phase 2Terminated20Apr 1, 2016Registry ↗
Jan 26, 2023Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
NCT02138786 · Richter's Transformation
selinexor
KPTI
Karyopharm Therapeutics Inc
Phase 2Terminated27Aug 31, 2016Registry ↗
Jan 26, 2023Selinexor (KPT-330) in Older Patients With Relapsed AML
NCT02088541 · Acute Myeloid Leukemia (AML)
Selinexor, Hydroxyurea
KPTI
Karyopharm Therapeutics Inc
Phase 2Completed317Jan 8, 2018Registry ↗
Jan 26, 2023Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
NCT02025985 · Ovarian Carcinoma, Endometrial Carcinoma
Selinexor
KPTI
Karyopharm Therapeutics Inc
Phase 2Completed116Jan 24, 2017Registry ↗
Jan 26, 2023Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Glio…
NCT01986348 · Glioblastoma, Glioma
Selinexor
KPTI
Karyopharm Therapeutics Inc
Phase 2Terminated76Jan 23, 2020Registry ↗
Jan 26, 2023Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
NCT01607905 · Solid Tumor
Selinexor, Acetaminophen
KPTI
Karyopharm Therapeutics Inc
Phase 1Completed192Mar 15, 2016Registry ↗
Jan 26, 2023Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced…
NCT01607892 · Hematological Malignancies
KPT-330
KPTI
Karyopharm Therapeutics Inc
Phase 1Completed286Oct 13, 2015Registry ↗
Jan 23, 2023Selinexor in Advanced Liposarcoma
NCT02606461 · Dedifferentiated Liposarcoma
Selinexor, Placebo
KPTI
Karyopharm Therapeutics Inc
Phase 2/3Completed342Oct 28, 2020Registry ↗
Jan 20, 2023Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With M…
NCT04355676 · Coronavirus Infection
Selinexor
KPTI
Karyopharm Therapeutics Inc
Phase 2Withdrawn0Aug 30, 2020Registry ↗
Jan 20, 2023Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
NCT04349098 · Coronavirus Infection
Selinexor, Placebo
KPTI
Karyopharm Therapeutics Inc
Phase 2Completed190Oct 5, 2020Registry ↗
Jan 20, 2023Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults
NCT02431364 · Healthy
Verdinexor, Placebo
KPTI
Karyopharm Therapeutics Inc
Phase 1Terminated33Oct 1, 2015Registry ↗
Jan 20, 2023Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ul…
NCT02367690 · Diabetic Foot Ulcers
Selinexor, Standard-of-Care
KPTI
Karyopharm Therapeutics Inc
Phase 1/2Withdrawn0May 2015Registry ↗

37 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:56 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances